{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:48:37Z","timestamp":1760237317275,"version":"build-2065373602"},"reference-count":10,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Fungal and parasitic diseases affect more than a billion people across the globe, one-sixth of the world\u2019s population, mostly located in developing countries. The lack of effective and safer treatments combined with a deficient diagnosis lead to serious chronic illness or even death. There is a mismatch between the rate of drug resistance and the development of new medicines. Formulation of antifungal and antiparasitic drugs adapted to different administration routes is challenging, bearing in mind their poor water solubility, which limits their bioavailability and efficacy. Hence, there is an unmet clinical need to develop vaccines and novel formulations and drug delivery strategies that can improve the bioavailability and therapeutic effect by enhancing their dissolution, increasing their chemical potency, stabilising the drug and targeting high concentration of drug to the infection sites. This Editorial regards the ten research contributions presented in the Special Issue \u201cAntifungal and Antiparasitic Drug Delivery\u201d.<\/jats:p>","DOI":"10.3390\/pharmaceutics12040324","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T05:59:47Z","timestamp":1586325587000},"page":"324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifungal and Antiparasitic Drug Delivery"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-1904","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Torrado","sequence":"first","affiliation":[{"name":"Departament of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-8420","authenticated-orcid":false,"given":"Dolores R.","family":"Serrano","sequence":"additional","affiliation":[{"name":"Departament of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0765-6403","authenticated-orcid":false,"given":"Javier","family":"Capilla","sequence":"additional","affiliation":[{"name":"Unitat de Microbiologia, Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat Rovira i Virgili and Institut d\u2019Investigaci\u00f3 Sanit\u00e0ria Pere Virgili (IISPV), 43201 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"T\u00e9llez-Mart\u00ednez, D., Portuondo, D.L., Loesch, M.L., Batista-Duharte, A., and Carlos, I.Z. (2019). A recombinant enolase-Montanide\u2122 Petgel A vaccine promotes a protective Th1 immune response against a highly virulent Sporothrix schenckii by toluene exposure. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11030144"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Alexandrino-Junior, F., Holanda e Silva, K.G., Freire, M.C.L.C., Lione, V.O.F., Azevedo Cardoso, E., Marcelino, H.R., Genre, J., Gomes de Oliveira, A., and Egito, E.S.T. (2019). A functional wound dressing as a potential treatment for cutaneous leishmaniasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11050200"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sosa, L., Calpena, A.C., Silva-Abreu, M., Espinoza, L.C., Rinc\u00f3n, M., Bozal, N., Domenech, O., Rodr\u00edguez-Lagunas, M.J., and Clares, B. (2019). Thermoreversible gel loaded amphotericin B for the treatment of dermal and vaginal candidiasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11070312"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Becerra-Sousa, A., Fern\u00e1ndez-Garc\u00eda, R., Rodr\u00edgues, G.F., Bol\u00e1s-Fern\u00e1ndez, F., Laurenti, M.D., Passero, L.F., Lalatsa, A., and Serrano, D.R. (2019). Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11070353"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Serrano, D.R., Fern\u00e1ndez-Garc\u00eda, R., Mele, M., Healy, A.M., and Lalatsa, A. (2019). Designing fast-dissolving orodispersible films of amphotericin B for oropharyngeal candidiasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080369"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Cantero, A., Serrano, D.R., Navarro-Rodr\u00edguez, P., Sch\u00e4tzlein, A.G., Uchegbu, I.F., Torrado, J.J., and Capilla, J. (2019). Increased efficacy of oral fixed-dose combination of amphotericin B and AHCC\u00ae natural adjuvant against aspergillosis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11090456"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Borrego-S\u00e1nchez, A., S\u00e1nchez-Espejo, R., Albertini, B., Passerini, N., Cerezo, P., Viseras, C., and Sainz-D\u00edaz, C.I. (2019). Ground calcium carbonate as a low cost and biosafety excipient for solubility and dissolution improvement of praziquantel. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11100533"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hsu, Y.-H., Chen, H.-Y., Chen, J.-C., Yu, Y.-H., Chou, Y.-C., Ueng, S.W.-N., and Liu, S.-J. (2019). Resorbable beads provide extended release of antifungal medication: In vitro and in vivo analyses. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11110550"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Berenguer, D., Sosa, L., Alcover, M., Sessa, M., Halbaut, L., Guill\u00e9n, C., Fisa, R., Calpena-Campmany, A.C., and Riera, C. (2019). Development and characterization of a semi-solid dosage form of meglumine antimoniate for topical treatment of cutaneous leishmaniasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11110613"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez, Y.J., Quejada, L.F., Villamil, J.C., Baena, Y., Parra-Giraldo, C.-M., and Perez, L.D. (2020). Development of amphotericin B micellar formulations based on copolymers of poly(ethylene glycol) and poly(\u025b-caprolactone) conjugated with retinol. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030196"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/4\/324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:15:25Z","timestamp":1760174125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/4\/324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["pharmaceutics12040324"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12040324","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2020,4,4]]}}}